Healthcare / Medical DevicesNasdaqGM
$1.67
+0.13 (+8.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-32.5M · quality 44.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$116M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-174.3%
↓Gross Margin
48.5%
↑Debt/Equity
4.04
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
+17.8%
FCF CAGR
—
FCF margin
-14.2%
FCF / Net income
0.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $149.2M · net income $-39.0M · FCF $-21.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $149.2M | $149.2M | $74.9M | $71.3M | $65.2M | $55.3M | $49.2M | $62.7M | $52.8M | $40.4M | $34.2M |
| Net Income | $-39.0M | $-39.0M | $-43.7M | $-30.2M | $-37.2M | $-31.2M | $-27.5M | $-29.0M | $-24.1M | $-16.1M | $-11.2M |
| EBITDA | $-28.1M | $-28.1M | $-35.2M | $-23.4M | $-32.0M | $-26.5M | $-21.4M | $-25.9M | $-19.0M | $-13.0M | $-8.7M |
| EPS | — | — | -1.37 | -1.05 | -1.38 | -1.22 | -1.46 | -1.58 | — | — | — |
| Gross Margin | 48.5% | 48.5% | 72.3% | 72.5% | 76.3% | 78.9% | 76.5% | 75.4% | 76.4% | 76.2% | 80.7% |
| Operating Margin | -21.1% | -21.1% | -46.2% | -42.8% | -53.8% | -49.8% | -45.3% | -43.0% | -37.6% | -33.7% | -27.3% |
| Net Margin | -26.1% | -26.1% | -58.4% | -42.3% | -57.0% | -56.4% | -55.7% | -46.4% | -45.7% | -39.7% | -32.8% |
| Balance Sheet | |||||||||||
| Debt/Equity | 4.04 | 4.04 | 2.98 | 1.83 | 0.70 | 0.41 | 1.36 | 0.42 | 0.43 | -0.15 | — |
| Current Ratio | 1.67 | 1.67 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-21.2M | $-21.2M | $-32.5M | $-34.4M | $-34.0M | — | — | — | — | — | — |
| Returns | |||||||||||
| ROE | -174.3% | -174.3% | -157.8% | -88.3% | -65.1% | -36.6% | -107.7% | -60.7% | -33.9% | 8.3% | 6.3% |
| Valuation | |||||||||||
| P/B | 5.15 | 5.15 | 1.70 | 2.51 | 3.12 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | 99.2% | 99.2% | 5.0% | 9.4% | — | 12.3% | -21.4% | 18.7% | 30.5% | 18.1% | — |
| EPS Growth | — | — | -30.5% | 23.9% | — | 16.4% | 7.6% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.37 → n/d
Residual
-57.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.